HK Stock Market Move | CRO concept stocks lead the gains. Recently, several overseas MNCs and CXOs have disclosed positive mid-year earnings and raised their full-year guidance.

CRO concept stocks are among the top gainers. As of the time of writing, WuXi AppTec (02359) has risen by 11.05% to HK$180.9; GENSCRIPT BIO (01548) is up 10.18% to HK$17.96; Asymchem Laboratories (06821) has gained 7.71% to HK$117.4; and WUXI BIO (02269) is up 3.92% to HK$40.34. In terms of news, WuXi AppTec announced that it achieved revenue of 28.897 billion yuan in the first half of the year, a year-on-year increase of 38.93%; net profit attributable to the parent company was 11.08 billion yuan, an increase of 29.43% year-on-year. The company also fully raised its performance guidance for the entire year of 2026, expecting total revenue to be adjusted from 51.3 billion - 53 billion yuan to 58.5 billion - 60.5 billion yuan, with the year-on-year growth rate for continuing operations revised up from 18%-22% to 35%-39%. It is worth noting that several overseas MNCs and CXOs have recently disclosed positive mid-year earnings surprises and raised their annual forecasts. Zhongtai stated that the demand side is gradually improving, with cyclical recovery logic continuing to unfold, and Q2 performance is expected to remain impressive. With the marginal improvement in the overseas biotech financing environment, the continued realization of Chinas innovative drug BD transactions, and the gradual advancement of commercialization projects, the industrys order side is expected to see a recovery.